source
- Par Health recalls two lots of Brevital Sodium injection over cellulose particlesPar Health announced a voluntary recall of two lots of its Brevital® Sodium 500 mg/vial for injection after detecting particulate matter identified as cellulose. The recall is being executed at th…
- Argenx's Vyvgart fails to beat placebo in Phase 3 Sjögren's disease trialArgenx announced that its marketed antibody therapy Vyvgart did not show superiority over placebo in a Phase 3 study involving patients with Sjögren's disease, a chronic autoimmune condition. The…